Friday 5 from Rheumatology Network - June 11

The Friday 5 from Rheumatology Network is a list composed by the Rheumatology Network editorial staff aimed at highlighting relevant coverage of the latest news in rheumatology.

This week, the Friday 5 from Rheumatology Network highlights the new 2021 treatment guidelines for rheumatoid arthritis as well as continues coverage for the European League Against Rheumatism (EULAR) 2021 Virtual Congress.

The 2021 Treatment Guidelines for Rheumatoid Arthritis

The American College of Rheumatology has updated its treatment guidelines for rheumatoid arthritis. The guideline includes 44 treatment recommendations, 7 of which are now strongly recommended.

Eugen Feist, MD: Olokizumab Emerges as Promising Therapy for Rheumatoid Arthritis

Rheumatology Network sat down with Eugen Feist, MD, to discuss the recent olokizumab data including the therapeutic prospects for olokizumab, its unique biologic mode of action, and the clinical significance of the phase III studies.

Jessica Walsh, MD: Patient Perspectives of Biologic Treatments for Axial Spondyloarthritis

Rheumatology Network spoke with Jessica Walsh, MD, to discuss her study, “Patient perspectives of biologic treatments for axial spondyloarthritis: satisfaction, wear-off between doses, and use of supplemental medications."

Alyssa Johnsen, MD, PhD: Guselkumab Improves Joint Symptoms and Skin Clearance in Psoriatic Arthritis

Alyssa Johnsen, MD, PhD, spoke with Rheumatology Network about the efficacy of guselkumab for psoriatic arthritis, the challenges of delivering safe and effective treatments in this patient population, and how guselkumab can help improve physical, social, and work activity for these patients.

Benjamin Nowell, PhD: Mindfulness Program for Patients With Rheumatic Disease

Rheumatology Network sat down for an interview with Benjamin Nowell, PhD, in partnership with CreakyJoints, to discuss the Healthy Mind Healthy You study, which assessed 2 mindfulness programs of varying lengths, designed for people with rheumatic disease, and compared the results.